MOTS-c vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | MOTS-c | Tesamorelin |
|---|---|---|
| Dose Range | 5 mg–10 mg | 2 mg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 8–12 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
What They Have in Common
MOTS-c, Tesamorelin are both commonly used for:
Key Differences
Unique to MOTS-c:
Which Has Stronger Evidence?
- Muscle Growth: Tesamorelin has stronger research support.
- Fat Loss: Tesamorelin has stronger research support.
| Goal | MOTS-c | Tesamorelin |
|---|---|---|
| Muscle Growth | low | medium |
| Fat Loss | medium | high |
Key Studies
MOTS-c
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.
Free radical biology & medicine, 2026
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.
Redox biology, 2025
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?
Cardiovascular drugs and therapy, 2025
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?